Please find attached.

IGL/SE/2026-27/51 1st September, 2026 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Mumbai – 400 001 Bandra (East), Mumbai- 400 051 Scrip Code: 500201 Symbol: INDIAGLYCO Dear Sirs, Sub: Disclosure under Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)- Effectiveness of the Scheme of Arrangement This is in continuation to our earlier intimation dated 21st August, 2026 bearing no: IGL/SE/2026-27/47,wherein we had informed about the effective date and record date for the Scheme of Arrangement amongst India Glycols Limited (“Demerged Company”/ “the Company”), Ennature Bio Pharma Limited (“Resulting Company 1”) and IGL Spirits Limited (“Resulting Company 2”) and their respective shareholders (“Scheme”) as sanctioned by the Hon’ble National Company Law Tribunal, Allahabad Bench (“NCLT”). We wish to inform you that in connection with the Scheme, all the aforesaid companies have filed the certified true copy of the Order of the NCLT with Registrar of Companies, Uttarakhand today i.e., 1st September, 2026. Accordingly, in terms of the provisions of the Clause 24 of the Scheme, the “Effective Date” of the Scheme is 1st September, 2026 and the Scheme contemplating the Demerger has now become effective and the Resulting Companies have ceased to be the subsidiaries of the Company. Further, a news release on Scheme of Arrangement is enclosed. You are requested to take the above information on record. Thanking you, Yours faithfully, For India Glycols Limited Ankur Jain Head (Legal) & Company Secretary Encls: A/a News Release India Glycols Limited Demerged into Three En(cid:415)(cid:415)es  India Glycols to operate as three separate en(cid:415)(cid:415)es from September 1, 2026  Shareholders to receive shares in each of the new en(cid:415)(cid:415)es Noida, September 1, 2026: India Glycols Limited, (NSE: INDIAGLYCO) (BSE: 500201), a leading green chemicals and manufacturing Company producing bio-based specialty chemicals, glycols, potable spirits and nutraceu(cid:415)cals, recently received approval from the Na(cid:415)onal Company Law Tribunal (NCLT) for the demerger of the Company into three en(cid:415)(cid:415)es. The demerger is effec(cid:415)ve September 1, 2026. On September 1, 2026, the original en(cid:415)ty, India Glycols Limited, demerges into three separate en(cid:415)(cid:415)es — India Glycols Limited, IGL Spirits Limited and Ennature Bio Pharma Limited. India Glycols Limited will house the chemicals, glycols, bio-glycols, new specialty products and industrial gases businesses. India Glycols reported a net revenue to Rs 345 crore in the June 2026 quarter. This en(cid:415)ty is already listed on both BSE and NSE. IGL Spirits Limited will house the spirits business, including IMFL, country liquor and bio-fuel businesses. IGL Spirits Limited reported a net revenue to Rs 694 crore in the June 2026 quarter. The management of IGL Spirits Limited will apply to BSE and NSE for lis(cid:415)ng of its shares on the respec(cid:415)ve bourses. Ennature Bio Pharma Limited will house the bio-pharma and bio-polymers businesses. Ennature Bio Pharma reported a net revenue to Rs 90 crore in the June 2026 quarter. The management of Ennature Bio Pharma Limited will apply to BSE and NSE for lis(cid:415)ng of its shares on the respec(cid:415)ve bourses. Shareholding Pa(cid:425)ern Each Shareholder of India Glycols on the record date of September 2, 2026, will be en(cid:415)tled to receive one equity share of IGL Spirits Limited for every one equity share held in India Glycols Limited, and one equity share of Ennature Bio Pharma Limited for every three equity shares held in India Glycols Limited. As a result, a Shareholder holding 300 India Glycols shares on September 2, 2026, will be en(cid:415)tled to receive 300 equity shares of IGL Spirits Limited and 100 equity share of Ennature Bio Pharma Limited, resul(cid:415)ng a total of 700 shares across the three en(cid:415)(cid:415)es, including the 300 equity shares held in India Glycols Limited. Benefits of the Demerger The demerger will result in the crea(cid:415)on of three separate companies, each with a clear business focus. Each company will have a dedicated focus, enabling improved management oversight and more efficient alloca(cid:415)on of resources towards growth. In addi(cid:415)on, each company will be able to manage its capital, investments and resources based on its specific business requirements, thereby enabling more efficient u(cid:415)lisa(cid:415)on of capital.